Last reviewed · How we verify
Placebo Testosterone
Placebo testosterone is an inert substance with no active pharmacological mechanism, used as a control in clinical trials to assess the psychological and contextual effects of testosterone treatment.
Placebo testosterone is an inert substance with no active pharmacological mechanism, used as a control in clinical trials to assess the psychological and contextual effects of testosterone treatment. Used for Control arm in testosterone replacement therapy clinical trials.
At a glance
| Generic name | Placebo Testosterone |
|---|---|
| Also known as | AndroGel, Testosterone enanthate, Androgel 1%, Transdermal Testosterone Gel, Fortesta® |
| Sponsor | Massachusetts General Hospital |
| Modality | Small molecule |
| Therapeutic area | Endocrinology |
| Phase | FDA-approved |
Mechanism of action
As a placebo, it contains no testosterone or active pharmaceutical ingredient. It is administered in clinical research settings to serve as a control arm, allowing researchers to distinguish between the physiological effects of actual testosterone replacement and the effects attributable to patient expectation, clinical attention, and other non-pharmacological factors.
Approved indications
- Control arm in testosterone replacement therapy clinical trials
Common side effects
Key clinical trials
- Oxandrolone Multiligament Knee (PHASE4)
- Acute Vitamin D Supplementation on Testosterone in Females (NA)
- A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy (PHASE3)
- Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening (PHASE4)
- Pain Alleviation With Testosterone in Opioid-Induced Hypogonadism (PHASE2)
- Investigating Novel Interventions for Low Back Pain in US Military Veterans: A Randomized Controlled Adaptive Phase II Trial (PHASE2)
- Does Human Skeletal Muscle Possess an Epigenetic Memory of Testosterone? (PHASE2, PHASE3)
- A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo Testosterone CI brief — competitive landscape report
- Placebo Testosterone updates RSS · CI watch RSS
- Massachusetts General Hospital portfolio CI